• Mashup Score: 0

    OverviewAt the New York Lung Cancers Symposium® attendees will experience a comprehensive overview of lung cancer diagnoses and multidisciplinary treatment. Now in its 18th year, the agenda for this meeting is designed to increase your knowledge of lung cancer therapy, including the roles that surgery, radiology, pulmonology, and pathology play to ensure the most accurate diagnosis of lung…

    Tweet Tweets with this article
    • Get ready to learn the latest data on immunotherapy and targeted agents in metastatic lung cancers and much more from #lungcancer experts at this year’s New York Lung Symposium! Register: https://t.co/p9a5gZ3kk7 #lscm #NYL23 #gotoPER @DrSteveMartin @MSKCancerCenter https://t.co/UnyKuznIY0

  • Mashup Score: 0

    The novel third-generation EGFR inhibitor abivertinib generated a positive overall response rate and overall survival in heavily pretreated Chinese patients with EGFR T790M–mutated non–small cell lung cancer who failed treatment on a first-line EGFR TKI, according to long-term follow-up data from a phase 1/2 trial (NCT02330367).

    Tweet Tweets with this article
    • Abivertinib generated a positive ORR and OS in pretreated Chinese patients w/ EGFR T790M–mutated NSCLC who failed treatment on a first-line EGFR TKI, according to long-term follow-up data from a phase 1/2 trial. #lscm https://t.co/4DlacDrOWI

  • Mashup Score: 17

    IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1% or more of tumour cells, and no new safety signals. Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with…

    Tweet Tweets with this article
    • Fresh out of #ESMO21 & published in @TheLancet 📰 IMpower0️⃣1️⃣0️⃣ ☑️ DFS benefit w/atezolizumab 🆚 BSC after adj chemo🧪in resected stage II–IIIA #NSCLC ☑️Benefit in subgroup w:PDL1 expression ✅A promising tx in resected early-stage NSCLC @OncoAlert 🚨 https://t.co/5fgOKinms8 https://t.co/epCWqrVM70

    • 🚨🚨 🔥🔥HOT OFF THE PRESS. #Impower 010 study just published @TheLancet Adjuvant #Atezolizumab after chemo in resected stage II-IIIA #NSCLC #LSCM #CancerEducation https://t.co/uTEPzhEcCh https://t.co/Rw4dLtU9Me